Last reviewed · How we verify
JDP-205 Injection
JDP-205 Injection is a monoclonal antibody targeting the PD-1 receptor.
JDP-205 Injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | JDP-205 Injection |
|---|---|
| Also known as | Cetirizine, Quzyttir |
| Sponsor | JDP Therapeutics, Inc. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, JDP-205 Injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg (PHASE1)
- A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers (PHASE1)
- Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria (PHASE3)
- Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JDP-205 Injection CI brief — competitive landscape report
- JDP-205 Injection updates RSS · CI watch RSS
- JDP Therapeutics, Inc. portfolio CI